



Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients

Marisol Zuniga^{1,8}, Claudia Gomes^{1,8}, Steven E. Carsons², Michael T. Bender³, Paolo Cotzia⁴, Qing Robert Miao⁵, David C. Lee^{6,7,9} and Ana Rodriguez^{1,9}

¹Dept of Microbiology, NYU Grossman School of Medicine, New York, NY, USA. ²Division of Rheumatology, Dept of Medicine, NYU Long Island School of Medicine, New York, NY, USA. ³Division of Pulmonology and Critical Care Medicine, Dept of Medicine, NYU Long Island School of Medicine, New York, NY, USA. ⁴Dept of Pathology, NYU Grossman School of Medicine, New York, NY, USA. ⁵Dept of Foundations of Medicine, NYU Long Island School of Medicine, New York, NY, USA. ⁶Dept of Emergency Medicine, NYU Grossman School of Medicine, New York, NY, USA. ⁷Dept of Population Health, NYU Grossman School of Medicine, New York, NY, USA. ⁸M. Zuniga and C. Gomes contributed equally to this work. ⁹D.C. Lee and A. Rodriguez contributed equally to this article as lead authors and supervised the work.

Corresponding author: David C. Lee (david.lee@nyumc.org)



Shareable abstract (@ERSpublications)

Levels of anti-annexin A2 antibodies at admission strongly predicted mortality among hospitalised COVID-19 patients. Given its critical protective function in the lung, annexin A2 antagonism may play an important role in the pathophysiology of COVID-19. <https://bit.ly/2UMPr9w>

Cite this article as: Zuniga M, Gomes C, Carsons SE, *et al.* Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients. *Eur Respir J* 2021; 58: 2100918 [DOI: 10.1183/13993003.00918-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2021.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 15 Jan 2021
Accepted: 24 June 2021

To the Editor:

The pathophysiology of severe coronavirus disease 2019 (COVID-19) has largely been attributed to a hyper-inflammatory response without a clear indication of the underlying mechanism [1]. There is a characteristic delay in the onset of respiratory distress, approximately 6 to 12 days after the start of symptoms, which is somewhat atypical for other severe viral respiratory infections [2]. Several theories have been proposed for this delay, such as an indolent infection or viral persistence. However, data from viral cultures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (not PCR) demonstrate a lack of positive cultures beyond day 9 of illness [3].

